Berberine ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance

被引：0
|
作者：
MacConell, L. [1 ]
Liberman, A. [1 ]
Flyer, A. [2 ]
Liu, K. [3 ]
机构：
[1] HighTide Therapeut, Rockville, MD USA
[2] PNW Stat Consulting, Woodinville, WA USA
[3] Shenzhen HighTide Biopharmaceut Ltd, Shenzhen, Peoples R China
来源：
DIABETOLOGIA | 2024年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
708
引用
收藏
页码：S339 / S339
页数：1
相关论文
共 13 条
  • [1] Berberine Ursodeoxycholate (HTD1801) provides a unique therapeutic approach for patients with metabolic diseases and severe insulin resistance
    MacConell, Leigh
    Liberman, Alexander
    Flyer, Abigail
    Liu, Kui
    JOURNAL OF HEPATOLOGY, 2024, 80 : S614 - S614
  • [2] Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
    Di Bisceglie, Adrian M.
    Watts, Gerald F.
    Lavin, Philip
    Yu, Meng
    Bai, Ru
    Liu, Liping
    LIPIDS IN HEALTH AND DISEASE, 2020, 19 (01)
  • [3] Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
    Adrian M. Di Bisceglie
    Gerald F. Watts
    Philip Lavin
    Meng Yu
    Ru Bai
    Liping Liu
    Lipids in Health and Disease, 19
  • [4] HTD1801 (berberbine ursodeoxycholate), a unique single molecule with multiple beneficial effects in metabolic and liver diseases
    Yu, Meng
    Bai, Ru
    Fu, Xinxiang
    Chen, Zhaobin
    Liu, Weijian
    MacConell, Leigh
    JOURNAL OF HEPATOLOGY, 2022, 77 : S669 - S669
  • [5] Efficacy of berberine ursodeoxycholate (HTD1801) in Chinese and Western patients with type 2 diabetes
    Gan, S.
    Ji, L.
    Ma, J.
    Cheng, Z.
    Gunn, N. T.
    Neff, G. W.
    Liu, K.
    MacConell, L.
    DIABETOLOGIA, 2024, 67 : S341 - S341
  • [6] GREATER BIOCHEMICAL IMPROVEMENTS WITH HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH PSC AND ELEVATED BASELINE ALKALINE PHOSPHATASE
    Forman, Lisa
    Kowdley, Kris V.
    Eksteen, Bertus
    Gunn, Nadege
    Sundaram, Vinay
    Landis, Charles
    Harrison, Stephen A.
    Levy, Cynthia
    Liberman, Alexander
    Di Bisceglie, Adrian M.
    Hirschfield, Gideon
    HEPATOLOGY, 2022, 76 : S1470 - S1472
  • [7] PROOF OF CONCEPT STUDY OF HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS NOT PREVIOUSLY EXPOSED TO UDCA
    Hirschfield, Gideon
    Forman, Lisa
    Eksteen, Bertus
    Gunn, Nadege T.
    Sundaram, Vinay
    Landis, Charles
    Harrison, Stephen A.
    Kohli, Anita
    Levy, Cynthia
    Di Bisceglie, Adrian M.
    Kowdley, Kris V.
    Floyd, Elson S.
    HEPATOLOGY, 2021, 74 : 73A - 73A
  • [8] TIME COURSE OF ONSET, INCIDENCE AND PREVALENCE OF GASTROINTESTINAL ADVERSE EVENTS WITH HTD1801 (BERBERINE URSODEOXYCHOLATE) IN PATIENTS WITH MASH AND T2DM
    Neff, Guy
    Harrison, Stephen
    Gunn, Nadege
    Flyer, Abigail
    Liu, Kui
    Liberman, Alexander
    HEPATOLOGY, 2024, 80
  • [9] Time course of onset, incidence and prevalence of gastrointestinal adverse events with HTD1801 (Berberine Ursodeoxycholate) in patients with MASH and T2DM
    Neff, Guy
    Harrison, Stephen A.
    Gunn, Nadege
    Flyer, Abigail
    Liu, Kui
    Liberman, Alexander
    JOURNAL OF HEPATOLOGY, 2024, 80 : S618 - S618
  • [10] EVALUATION OF EFFICACY OF BERBERINE URSODEOXYCHOLATE (HTD1801) COMPARED TO ONGOING USE OF GLP-1 RECEPTOR AGONISTS IN PATIENTS WITH MASH AND T2DM
    Harrison, Stephen
    Neff, Guy
    Gunn, Nadege
    Flyer, Abigail
    MacConell, Leigh
    HEPATOLOGY, 2024, 80
12